Abstract
Objectives: LUM/IVA has been shown to be safe and effective in people with CF, including children. This registry-based study evaluated long-term efficacy and safety of LUM/IVA in children aged 2 through 5 years at treatment initiation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
